Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 400 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 800 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 100 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 25 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 40 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 60 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 80 mg

Unione Europea - islandese - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Æxlishemjandi lyf - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rabeprazolum natríum - magasýruþolin tafla - 20 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - glucosum - innrennslislyf, lausn - 50 mg/ml